FEASIBILITY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY IN ADVANCED PEDIATRIC SOLID TUMORS

REFERENCES

• Chan KW, Petropoulos D, Choroszy M, . High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant. 1997;20:1039–1043.
   PubMedGoogle Scholar
• Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348–357.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Krailo MD, Ladanyi M, . High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812–281220.
   PubMed Web of Science ®Google Scholar
• Berthold F, Boos J, Burdach S, . Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–658.
   PubMed Web of Science ®Google Scholar
• Kletzel M, Katzenstein HM, Haut PR, . Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002;20:2284–2292.
   PubMed Web of Science ®Google Scholar
• George RE, Li S, Medeiros-Nancarrow C, . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–2896.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Barrett A, . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874–1881.
   PubMed Web of Science ®Google Scholar
• Won SC, Han JW, Kwon SY, . Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: a report from the Korean Society of Pediatric Hematology–Oncology. Ann Hematol. 2006;85:787–794.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Philip T, Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr. 1997;9:55–69.
   Google Scholar
• Imaizumi M, Watanabe A, Kikuta A, . Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group. Tohoku J Exp Med. 2001;195:73–83.
   Google Scholar
• Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther. 2006;6:225–237.
   PubMed Web of Science ®Google Scholar
• Atra A, Pinkerton R. High-dose chemotherapy in soft tissue sarcoma in children. Crit Rev Oncol Hematol. 2002;41:191–196.
   Google Scholar
• Verlooy J, Mosseri V, Bracard S, . Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer. 2006;42:3004–3014.
   PubMed Web of Science ®Google Scholar
• Suita S, Shono K, Tajiri T, . Malignant germ cell tumors: clinical characteristics, treatment, and outcome: a report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg. 2002;37:1703–1706.
   PubMedGoogle Scholar
• Sung KW, Yoo KH, Cho EJ, . High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer. 2007;48:408–415.
   PubMedGoogle Scholar
• Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors—Bulgarian experience. J Buon. 2006;11:433–438.
   Google Scholar
• Marcus KJ, Shamberger R, Litman H, . Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol. 2003;25:934–940.
   Google Scholar
• Pradhan KR, Johnson CS, Vik TA, Sender LS, Kreissman SG. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer. 2006;46:793–802.
   Google Scholar
• Jakacki RI, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med Pediatr Oncol. 1997;2:553–559.
   Google Scholar
• Strother D, Ashley D, Kellie SJ, . Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001;19:2696–2704.
   PubMed Web of Science ®Google Scholar
• Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008;41:159–165.
   PubMed Web of Science ®Google Scholar
• Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol. 1997;19:309–312.
   Google Scholar
• Basser RL, To LB, Begley CG, . Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. J Clin Oncol. 1998;16:1899–1908.
   Google Scholar
• Shapiro CL, Ayash L, Webb IJ, . Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997;15:674–683.
   Google Scholar
• Bokemeyer C, Gillis AJ, Pompe K, . Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. J Clin Oncol. 2001;19:3029–3036.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, . Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165–1173.
   PubMed Web of Science ®Google Scholar
• Stram DO, Matthay KK, O'Leary M, . Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996;14:2417–2426.
   PubMedGoogle Scholar
• Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22:4888–4892.
   Google Scholar